摘要
目的探讨紫杉醇联合卡铂治疗晚期卵巢癌的临床疗效及对肿瘤标志物和不良反应的影响。方法将176例晚期卵巢癌患者依据治疗方案的不同分为对照组(紫杉醇+顺铂治疗,n=87)和观察组(紫杉醇+卡铂治疗,n=89)。比较两组患者的临床疗效、肿瘤标志物[糖类抗原125(CA125)、血管内皮生长因子(VEGF)、人附睾蛋白4(HE4)]水平、不良反应发生情况及肿瘤远处转移情况。结果观察组患者总有效率高于对照组,差异有统计学意义(P﹤0.05)。治疗后,两组患者CA125、VEGF及HE4水平均下降,且观察组患者CA125、VEGF及HE4水平均低于对照组,差异均有统计学意义(P﹤0.05)。观察组患者不良反应发生情况优于对照组,差异有统计学意义(P﹤0.05)。两组患者远处转移率比较,差异无统计学意义(P﹥0.05)。结论紫杉醇联合卡铂治疗晚期卵巢癌的临床疗效显著,可有效降低患者肿瘤标志物水平,减轻不良反应,安全性高。
Objective To investigate the efficacy of paclitaxel combined carboplatin in the treatment of advanced ovarian cancer and its effect on tumor markers and adverse reactions.Method A total of 176 patients with advanced ovarian cancer were divided into control group(n=87,treated with paclitaxel+cisplatin)and observation group(n=89,treated with paclitaxel+carboplatin)according to different treatment methods.The clinical efficacy,tumor markers[carbohydrate antigen 125(CA125),vascular endothelial growth factor(VEGF),and human epididymis protein 4(HE4)],adverse reactions and distant metastasis of tumors were compared between the two groups.Result The total effective rate of observation group was higher than that of control group(P<0.05).After treatment,the levels of CA125,VEGF and HE4 decreased in both groups,with lower levels in the observation group than those in the control group(P<0.05).The occurrence situation of adverse reactions in observation group was better than that in control group(P<0.05).There was no significant difference for the distant metastasis rate of tumors in the two groups(P>0.05).Conclusion Paclitaxel+carboplatin has significant clinical efficacy in the treatment of advanced ovarian cancer,which can effectively reduce the level of tumor markers and adverse reactions with high safety.
作者
杨庆蕊
王文翔
杨静
张孝松
王聪
YANG Qingrui;WANG Wenxiang;YANG Jing;ZHANG Xiaosong;WANG Cong(Department of Pharmacy,Xinxiang Central Hospital(the Fourth Clinical College,Xinxiang Medical University),Xinxiang 453000,He’nan,China;Department of Gynecology,Xinxiang Central Hospital(the Fourth Clinical College,Xinxiang Medical University),Xinxiang 453000,He’nan,China)
出处
《癌症进展》
2023年第24期2742-2745,共4页
Oncology Progress
基金
2021年度河南省医学科技攻关计划联合共建项目(LHGJ20210914)。
关键词
紫杉醇
卡铂
晚期卵巢癌
临床疗效
不良反应
paclitaxel
carboplatin
advanced ovarian cancer
clinical efficacy
adverse reaction
